Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

758

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Non-Small Cell

Interventions

BIOLOGICAL: Cobolimab
BIOLOGICAL: Dostarlimab
DRUG: Docetaxel

Sponsor

GlaxoSmithKline